David Chang, M.D., Ph.D.

David Chang, M.D., Ph.D.

President and Chief Executive OfficeratAllogene Therapeutics· In proxies 2021–2025

Pay in FY2022+46% from the year before · Allogene Therapeutics stock -57.8% the same year

David Chang, M.D., Ph.D. was paid $14.8M in FY2022 (Dec), up 46%. Allogene Therapeutics stock fell 57.8% that year.

Pay$100 in the stock at the end of FY20 → $25
Pay is from the Summary Compensation Table of each Allogene Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Allogene TherapeuticsPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrStock in role -95%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?